Alectinib and dacomitinib show potential in separate trials for lung cancer
Data from two separate Phase III clinical trials of lung cancer drugs that target different gene faults in the disease, alectinib (Alecensa) and dacomitinib, indicated promise when compared to existing medication.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news